News & Information
At Memorial Sloan Kettering, our leading edge research is constantly advancing what we know about cancer and new discoveries are improving care for patients here, and all over the world. In News and Information, you will find information about our groundbreaking work and the dedicated professionals who make it all happen.
Connect with us to reach MSK experts for media inquiries and for story ideas.
A Tradition of Excellence: See Why U.S. News & World Report Has Consistently Named MSK a Top Cancer Hospital in the Nation
For more than three decades, U.S. News & World Report has recognized Memorial Sloan Kettering as one of the top two cancer hospitals in the country. This year was no different. Our compassionate and dedicated staff have led us here. Learn more about them and our thoughtful, empathetic approach to cancer care.
Memorial Sloan Kettering Cancer Center Ranked Among the Best Hospitals for Cancer Care by U.S. News & World Report for 33 Consecutive Years
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since these prestigious rankings were established more than 30 years ago, MSK has consistently ranked among the top two cancer hospitals in the country.
For more than 137 years, MSK has made historic contributions driving discovery and improving patient care. Take a look back at the progress we've made since the signing of the National Cancer Act in 1971.
In the News
Learn how MSK researchers are deploying mRNA vaccines against pancreatic cancer.
African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.
A groundbreaking clinical trial is testing CAR T cells created using CRISPR gene-editing technology.
ASCO 2023: Memorial Sloan Kettering Cancer Center Experts to Present Leading Edge Research at the American Society of Clinical Oncology Annual Meeting
Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2–6 in Chicago.
Memorial Sloan Kettering Cancer Center Announces $40M Gift To Establish The Marie-Josée Kravis Center for Cancer Immunobiology To Advance Immunotherapy Research
The Marie-Josée Kravis Center for Cancer Immunobiology (CCI), made possible by a generous $40 million gift from Henry R. Kravis to honor the visionary leadership of his wife, Marie-Josée Kravis, will establish a strategic research infrastructure that will seamlessly unite MSK scientists and physicians to further accelerate immunotherapy treatments for people with cancer.
Since 2019, the Robbins Family Foundation has sponsored awards to honor MSK nurses’ extraordinary achievements and contributions to MSK’s mission and core values.
Memorial Sloan Kettering Cancer Center has announced a $40 million gift from Henry R. Kravis to establish a hub for immunotherapy research. MSK’s Joan Massagué is quoted.
Wednesday, May 31, 2023
Forbes list “America’s Best Employers for New Grads”. MSK is listed.
Tuesday, May 23, 2023
The Society of Memorial Sloan Kettering Cancer Center held its 16th annual Spring Ball at the elegant Pierre Hotel, generously hosted by De Beers. Each year, the Spring Ball hosts over 400 of MSK’s most high-profile supporters with the ongoing mission of funding patient care and research at the hospital. MSK’s Lisa DeAngelis and T. Peter Kingham are quoted.
Monday, May 22, 2023
News from the Lab
Rather than promoting genetic chaos, loss of p53 leads to an orderly progression of genetic changes that no one saw coming.
Researchers learn how prostate cancer cells change their type to survive treatment.
Learn why MSK researchers developed MACHETE, a new CRISPR-based technique to study large-scale genetic deletions efficiently in laboratory models.
Symantha Wilson was crushed when chemotherapy quit fighting her lymphoma — and thrilled when immuno¬therapy beat back the cancer. But why doesn’t immunotherapy help more people? MSK researchers are finding answers.
This new era of cancer research investigates how the disease in certain locations interacts with all the body’s systems. Focusing on cancer’s ecosystem promises to reveal lifesaving insights, especially into metastasis.
To help some patients to overcome leukemia, MSK doctors are calling upon patients’ microbiomes — the vast ecosystems of microorganisms that live within us, especially the gut. These microbes appear to help some patients recover from bone marrow and stem cell transplants.
2022 Annual Report: It Takes MSK
Learn how a heralded clinical trial at Memorial Sloan Kettering Cancer Center is being expanded that made rectal cancer disappear in every participant using only immunotherapy that targets a rare mutation — without the need for surgery, chemotherapy, or radiation.
MSK-led research could change the practice of medicine for millions of people whose breast cancer has spread. Research led by Dr. Shanu Modi has demonstrated that a targeted drug called trastuzumab deruxtecan blocks the protein HER2 even when its levels are low — the case for about 55% of people with breast cancer.
The protein made by the p53 gene helps guard the body against cancer, in part by detecting and repairing damaged DNA. Over the 30 years since p53 was first discovered, it has remained a stubborn mystery, resisting efforts to tease apart exactly how the loss of the gene’s protection leads to the development of cancer. In August 2022, researchers in the Sloan Kettering Institute were able to provide some new answers that hint at new avenues for treatment.